Combination antiretroviral therapy: Industries
Industries
The industries and kinds of firm that use or make it, how far they have taken it up and what it does to them
Made by- Innovator pharma and biotech companies New drug classes Research-based drug companies, with NIH-funded research, developed the drug classes from AZT in 1987 onwards [1].
- Finished-dose formulators (branded and generic) low-cost generics Generic producers in countries such as India, Brazil and Thailand [4] helped bring the lowest first-line price to $100 a year by 2016 [5].
- Primary care clinics and doctors' practices Lifelong treatment Clinics test, treat and monitor 32.1 million people on treatment in 2025 [2].
- Public hospitals, schools and universities National programmes Public health programmes fund and run treatment; US$ 17.6 billion was available in poorer countries at the end of 2025 [2].
as of 2026-11-11
Sources
- Antiretroviral Drug Discovery and Development National Institute of Allergy and Infectious Diseases (NIH)
- Fact sheet 2026 UNAIDS, 2026
- The impact of patents on access to medicines MSF Access Campaign (Médecins Sans Frontières), 2017
- Untangling the Web of Antiretroviral Price Reductions, 18th edition Médecins Sans Frontières Access Campaign, copy at AIDS Data Hub, 2016, p. 3